TB CAB

TB CAB, CRAG, TAG open letter to AstraZeneca

Community groups express concern for AstraZeneca's departure from tuberculosis and urge the company to ensure continued investment in the field.

Read More →

TB CAB, TAG public comment in response to FDA guidance to TB drug developers

Comment on Guidance for industry on pulmonary tuberculosis: Developing drugs for treatment.

Read More →

TB CAB, TAG open letter to Cepheid

Re: GeneXpert machine and Xpert MTB/RIF cartridge pricing, extended warranties and business in Russia and the People’s Republic of China

Read More →

TB CAB, CRAG, TAG open letter to Otsuka

Re: Urgent appeal to initiate delamanid compassionate use program

Read More →

TAG, TB CAB open letter to Alere

Re: Responsible marketing and access plans for Alere’s Determine TB-­LAM antigen test for active TB

Read More →

TAG, TB CAB open letter to Sequella

Re: Further research into sutezolid urgently needed for tuberculosis

Read More →

TAG, TB CAB, India CAB open letter to Immunoshop

Re: Marketing and use of TB Platinum for active TB in India and high TB burden countries

Read More →

TAG, TB CAB, India CAB open letter to Qiagen

Re: Marketing and use of QuantiFERON-TB Gold for active TB in India and high TB burden countries

Read More →

TB CAB open letters on EU-India FTA

Open letters to Indian Prime Minister and Health Minister to support India’s refusal of any Trade-Related Aspects of Intellectual Property Rights (TRIPS)-Plus Provisions in Free-Trade Agreement negotiations with the European Union.

Read More →

TB CAB: Open letter to the European Medicines Agency

Open letter to the European Medicines Agency regarding the filing of the drugs delamanid and bedaquiline for market approval.

Read More →

Page 4 of 5 · Total posts: 10

←First 3 4 5 Last→